Actors involved in the bio-pharmaceutical industry are constantly called to take decisions regarding reimbursement of drugs or health care budget allocation under uncertainty. These decisions regard not only pharmaceutical or biotechnological companies, but also local institutions aiming at a more effective budgeting of health care.
ATA provides a range of suitable methodologies to help potential clients to make sense of data and effectively solve their decision analysis problems.
In contrast to traditional tools for decision making, ATA combines economic expertise with the most advanced statistical tools, such as decision trees and Markov models, Bayesian Networks and Influence Diagrams, that have not been frequently used in pharmacoeconomics.
|
 |
|
|
| |
 |
|
| |
Health technology assessment plays an essential role in modern health care by supporting effective decision making in health care policy and practice.
|
|
| |
 |
|
| |
|
|
|
Our tools are characterized by high ability in representing probabilistic structure, therefore facilitating communication between analysts and experts; and their computational facilities, Decision-Theoretic Networks provide a useful expansion of the analytic tools in pharmacoeconomics ( read more on Decision-Theoretic Networks).
This combination results in comprehensive evaluations and assessment of evidence, such as cost-benefit and cost-effectiveness evaluations or budget impact analysis, currently required by the most important regulatory institutions across the world.
Please see our paper on Cost Effectiveness Analysis of Influenza Vaccination in Italian Elderly Population.
For further information, please contact us at info@atalab.com
|
